Therapeutic Area: Oncology
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank et al.
Nature Medicine
November 2018
Authors and Affiliates
Blank CU1,2, Rozeman EA3,4, Fanchi LF4, Sikorska K5, van de Wiel B6, Kvistborg P4, Krijgsman O4, van den Braber M4, Philips D4, Broeks A6, van Thienen JV3, Mallo HA3, Adriaansz S3, Ter Meulen S7, Pronk LM5, Grijpink-Ongering LG5, Bruining A8, Gittelman RM9, Warren S10, van Tinteren H5, Peeper DS4, Haanen JBAG3,4, van Akkooi ACJ7, Schumacher TN11.
1
Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.
2
Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. c.blank@nki.nl.
3
Medical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
4
Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
5
Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
6
Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
7
Surgical Oncology Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.
8
Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
9
Adaptive Biotechnologies, Seattle, WA, USA.
10
NanoString Technologies, Inc., Seattle, WA, USA.
11
Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.schumacher@nki.nl.
Early expansion of donor-specific Tregs in tolerant kidney transplant recipients
Authors and Affiliates
Savage TM1, Shonts BA1, Obradovic A1, Dewolf S1, Lau S1, Zuber J1, Simpson MT1, Berglund E1, Fu J1, Yang S1, Ho SH1, Tang Q2, Turka LA3,4, Shen Y5, Sykes M1,6,7
1 Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
2 Department of Surgery, University of California San Francisco, San Francisco, California, USA.
3 Center for Translational Sciences, Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
4 Immune Tolerance Network, Bethesda, Maryland, USA.
5 Center for Computational Biology and Bioinformatics, Department of Systems Biology, Columbia University, New York, New York, USA.
6 Department of Microbiology & Immunology, Columbia University Medical Center, Columbia University, New York, New York, USA.
7 Department of Surgery, Columbia University Medical Center, Columbia University, New York, New York, USA.
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Naing et al.
Cancer Cell
November 2018
Authors and Affiliates
Naing A1, Infante JR2, Papadopoulos KP3, Chan IH4, Shen C5, Ratti NP4, Rojo B4, Autio KA5, Wong DJ6, Patel MR7, Ott PA8, Falchook GS9, Pant S10, Hung A4, Pekarek KL4, Wu V4, Adamow M5, McCauley S4, Mumm JB4, Wong P5, Van Vlasselaer P4, Leveque J4, Tannir NM1, Oft M11.
1 MD Anderson Cancer Center, Houston, TX, USA.
2 Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN, USA.
3 START Center for Cancer Care, San Antonio, TX, USA.
4ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA.
5Memorial Sloan Kettering Cancer Center, New York, NY, USA.
6 University of California Los Angeles (UCLA), Los Angeles, CA, USA.
7 Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, USA.
8 Dana-Farber Cancer Institute, Boston, MA, USA.
9 Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
10 Oklahoma University, Oklahoma City, OK, USA.
11 ARMO BioSciences, Eli Lilly and Company, Redwood City, CA, USA. Electronic address: martinoft@gmail.com.
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
Tarhini et al.
Journal for ImmunoTherapy of Cancer
October 2018
Authors and Affiliates
Tarhini A1,2, Lin Y3, Lin H3, Rahman Z3, Vallabhaneni P3, Mendiratta P4, Pingpank JF3, Holtzman MP3, Yusko EC5, Rytlewski JA5, Rao UNM3, Ferris RL3, Kirkwood JM3
1 UPMC Hillman Cancer Center, Pittsburgh, USA. tarhina1@ccf.org.
2 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, 9500 Euclid Ave CA6-157, Cleveland, OH, 44195, USA. tarhina1@ccf.org.
3 UPMC Hillman Cancer Center, Pittsburgh, USA.
4 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, 9500 Euclid Ave CA6-157, Cleveland, OH, 44195, USA.
5 Adaptive Biotechnologies, Seattle, USA.
HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis
Poonia et al.
Scientific Reports
October 2018
Authors and Affiliates
Bhawna Poonia,1 Natarajan Ayithan,1 Madhuparna Nandi,1 Henry Masur,2 and Shyam Kottilil1
1Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201 USA
2Critical Care Medicine Department, NIH Clinical Center, Bethesda, MD 20892 USA
Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
Mansfield et al.
Journal of Thoracic Oncology
October 2018
Authors and Affiliates
Mansfield AS1, Peikert T2, Smadbeck JB3, Udell JBM4, Garcia-Rivera E5, Elsbernd L6, Erskine CL6, Van Keulen VP6, Kosari F3, Murphy SJ3, Ren H7, Serla VV3, Schaefer Klein JL3, Karagouga G3, Harris FR3, Sosa C3, Johnson SH3, Nevala W6, Markovic SN1, Bungum AO2, Edell ES2, Dong H8, Cheville JC7, Aubry MC7, Jen J9, Vasmatzis G10
1 Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
2 Division of Pulmonary Medicine and Critical Care, Mayo Clinic, Rochester, Minnesota.
3 Center for Individualized Medicine, Biomarker Discovery Group, Mayo Clinic, Rochester, Minnesota.
4 Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
5 nference, Cambridge, Massachusetts.
6 Department of Immunology, Mayo Clinic, Rochester, Minnesota.
7 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
8 Department of Immunology, Mayo Clinic, Rochester, Minnesota; Department of Urology, Mayo Clinic, Rochester, Minnesota.
9 Medical Genome Facility, Mayo Clinic, Rochester, Minnesota.
10 Center for Individualized Medicine, Biomarker Discovery Group, Mayo Clinic, Rochester, Minnesota. Electronic address: vasmatzis.george@mayo.edu
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
Yossef et al.
JCI Insight
October 2018
Authors and Affiliates
Yossef R1, Tran E1,2, Deniger DC1, Gros A1,3, Pasetto A1, Parkhurst MR1, Gartner JJ1, Prickett TD1, Cafri G1, Robbins PF1, Rosenberg SA
1 Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA.
2 Earle A. Chiles Research Institute and the Providence Portland Medical Center, Portland, Oregon, USA.
3 Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Pg. Vall d'Hebron, Barcelona, Spain.
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Authors and Affiliates
Ruella M1,2,3,4,5, Xu J1,2,3, Barrett DM6, Fraietta JA1,2,3,4, Reich TJ1, Ambrose DE1, Klichinsky M1,7, Shestova O1, Patel PR1, Kulikovskaya I1, Nazimuddin F1, Bhoj VG1,2,3, Orlando EJ8, Fry TJ9, Bitter H8, Maude SL6, Levine BL1,2,3, Nobles CL10, Bushman FD10, Young RM1, Scholler J1, Gill SI1,3,5, June CH11,12,13,14, Grupp SA6, Lacey SF1,2,3, Melenhorst JJ15,16,17.
1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
2
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
3
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
4
Parker Institute for Cellular Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA.
5
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
6
Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
7
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
8
Novartis Institutes for Biomedical Research, Cambridge, MA, USA.
9
University of Colorado, Children's Hospital Colorado, Denver, CO, USA.
10
Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
11
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
12
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
13
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
14
Parker Institute for Cellular Immunotherapy at the University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu.
15
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
16
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
17
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria et al.
Nature Medicine
Papers
October 2018
Authors and Affiliates
Rodabe N. Amaria1, Sangeetha M. Reddy2, Hussein A. Tawbi1, Michael A. Davies1, Merrick I. Ross3, Isabella C. Glitza1, Janice N. Cormier3, Carol Lewis4, Wen-Jen Hwu1, Ehab Hanna4, Adi Diab1, Michael K. Wong1, Richard Royal3, Neil Gross4, Randal Weber4, Stephen Y. Lai4, Richard Ehlers3, Jorge Blando5, Denái R. Milton6, Scott Woodman1, Robin Kageyama7, Danny K. Wells7, Patrick Hwu1, Sapna P. Patel1, Anthony Lucci3, Amy Hessel4, Jeffrey E. Lee3, Jeffrey Gershenwald3, Lauren Simpson1, Elizabeth M. Burton3, Liberty Posada1, Lauren Haydu3, Linghua Wang8, Shaojun Zhang8, Alexander J. Lazar 9, Courtney W. Hudgens 9, Vancheswaran Gopalakrishnan3, Alexandre Reuben3, Miles C. Andrews3, Christine N. Spencer8, Victor Prieto9, Padmanee Sharma5,10, James Allison5, Michael T. Tetzlaff9,11 and Jennifer A. Wargo3,8
1Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 2Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 3Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. 4Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA. 5Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA. 6Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA. 7Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. 8Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA. 9Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA. 10Department of Genitourinary Cancers, MD Anderson Cancer Center, Houston, TX, USA. 11Department of Translational and Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA.